Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia
Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia
复制标题
DOI：
10.1016/s0920-9964(00)00026-8
复制
发表时间：
2000-12-15
影响因子：
4.5
通讯作者：
Advokat, C
中科院分区：
文献类型：
--
作者：
Combs, DR;Advokat, C
据报道，非典型抗精神病药氯氮平可减少精神分裂症患者的吸烟。我们试图确定其他非典型抗精神病药物是否也与该人群吸烟患病率下降相关。数据来自三组慢性住院精神分裂症患者，接受典型抗精神病药（n=15）、氯氮平（n=6）或另一种非典型抗精神病药（n=18）。除了吸烟率，还比较了人口统计学（年龄，教育），药物（剂量，治疗持续时间，副作用），临床（诊断，疾病持续时间）和行为（广泛成就测试，Wechsler成人智力量表）变量。吸烟率在三组间差异有统计学意义（P
The atypical antipsychotic, clozapine, has been reported to reduce smoking in schizophrenic patients. We sought to determine whether other atypical antipsychotics would also be associated with a decreased prevalence of smoking in this population. Data were obtained from three groups of chronic, hospitalized, schizophrenic patients, receiving either a typical antipsychotic (n=15), clozapine (n=6), or another atypical antipsychotic (n=18). In addition to smoking prevalence, the groups were compared with regard to demographics (age, education), medication (doses, duration of treatment, side-effects), clinical (diagnosis, duration of illness) and behavioral (Wide-Range Achievement Test, Wechsler Adult Intelligence Scale) variables. Smoking prevalence differed significantly among the three groups (P